ViewRay chooses Denver for its headquarters

Innovative Cancer Therapy Company to Leverage Colorado bioscience talent resources

DENVER, August 8, 2022 /PRNewswire/ — View Ray, Inc.. (Nasdaq: VRAY), a medical device company that designs, manufactures and markets the MRIdian® Radiation Therapy Systemtoday announced the transfer of its headquarters to Denver, Colorado as it continues to attract top talent from the state’s growing medical technology sector. Event details to follow:

What:

Opening of ViewRay Headquarters

When:

Mon 15 Aug 2022

Time:

1 p.m.

Where:

The Granite Tower, 1099 18e Street, 3rd Floor, Denver, CO 80202

Notes from:

  • Jared PolisGovernor, state of colorado
  • Michael Hancock, Mayor, City of Denver
  • Scott Drake, President and CEO, ViewRay

Mid-2019, ViewRay opened an office in denver start with less than ten teammates. The presence of ViewRay in denver has now grown to more than 50 teammates with the expansion of the company’s international marketing, finance and legal teams. ViewRay is one of the fastest growing companies in the medical technology industry with plans for considerable growth in denver.

ViewRay plans to continue to develop its denver team with additional high-paying roles in product development, manufacturing, and quality, and in 2023 the company plans to add another building focused on development, manufacturing, and physician training.

Colorado is home to a strong bioscience industry, making Mile High City a great place to do business and introduce clinicians to life-saving radiation therapy. According to the Colorado Bioscience Association:

  • Colorado is home to 720 life science companies and organizations.
  • More than 32,000 people are directly employed by the biosciences industry, an average $96,000 annual salary.
  • Subway denver on the 8the the largest medical device industry in the United States

Over the past 20 years, ViewRay CEO Scott Drake and the ViewRay leadership team have created more than 3,000 medical technology jobs. Colorado.

“We are proud to host the headquarters of ViewRay Coloradoan exciting initiative that brings well-paying jobs to Coloradans,” Governor Polis said. “As we continue to save people money and support small businesses, Colorado remains the best place to live, work and do business.”

“ViewRay is moving to denver create more opportunities for our tech talent base and continue to elevate our community as a center of healthcare innovation. Guided by the values ​​of a healthy community and healthy community engagement, we couldn’t be prouder that they chose our great city to fulfill their ambitious mission to improve cancer treatment technology and ultimately to saving thousands of lives,” denver Mayor Michael B. Hancock said.

“ViewRay is delighted that Colorado will be the international headquarters for this innovative cancer therapy. The state is a magnet for talented professionals and scholars in our field and is rapidly becoming a center of the international bioscience industry,” said Scott Drake President and CEO of ViewRay. “We look forward to growing as a company, but more importantly, we are committed to defeating cancer by rethinking radiation therapy, because lives depend on it. Patients deserve short-term, non-invasive therapy with fewer side effects and better quality of life. , whether they face complex or more common forms of cancer. ViewRay is committed to providing this to every patient requiring treatment. »

About MRIdian
Radiation therapy treatment works by delivering radiation to tumor sites. However, clinicians must limit the amount of radiation delivered to the tumor to preserve surrounding healthy tissues and organs. With conventional technology, clinicians do this by spreading the amount of radiation given over several weeks by having the patient come in for 20-30-40 treatments. In short, they face a trade-off between safety and efficiency; as well as quality of life depending on the treatment schedule.

The MRIdian system provides oncologists with exceptional anatomical visualization through diagnostic-quality MRI images and the ability to tailor a radiation treatment plan to the targeted cancer with the patient on the table. This combination allows physicians to set narrow treatment margins to avoid unnecessary radiation exposure to vulnerable organs at risk and healthy tissues and allows the delivery of ablative radiation doses in five treatment sessions or less, without relying on implanted markers. By providing real-time, continuous tracking of the target and organs at risk, MRIdian enables automatic radiation beam triggering if the target moves outside of user-defined margins. This allows the prescribed dose to be delivered to the target, while sparing surrounding healthy tissue and critical structures, minimizing the toxicities typically associated with conventional radiation therapy.

Nearly 25,000 patients have been treated with IRMdian. Currently, 53 MRI systems are installed in hospitals around the world where they are used to treat a wide variety of solid tumors and are the subject of many ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts and presentations. For a list of treatment centers, please visit: https://viewray.com/find-mridian-mri-guided-radiation-therapy/

About ViewRay
ViewRay, Inc. (Nasdaq: VRAY) designs, manufactures and markets the MRIdian MRI-guided radiation therapy system. MRIdian is built on a proprietary high-definition MR imaging system designed from the ground up to meet the unique challenges and clinical workflow of advanced radiation oncology. Unlike MRI systems used in diagnostic radiology, MRIdian’s high-definition MRI has been specifically designed to address specific challenges including beam distortion, skin toxicity, and other issues that can arise when high magnetic fields interact with beams of radiation. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

Forward-looking statements
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. These forward-looking statements include, among other things, ViewRay’s financial forecast for the full year 2022, expected future orders, expected future operational and financial performance, treatment outcomes, therapy uptake, innovation and performance of MRIdian systems. Actual results could differ from those projected in the forward-looking statements due to many factors. These factors include, among others, the ability to commercialize the MRIdian Linac System, demand for ViewRay’s products, ability to convert backlog into revenue, timing of delivery of ViewRay’s products, timing, and the severity of the COVID-19 pandemic, including its impacts on our on-demand business, global operations and supply chains, results and other uncertainties associated with clinical trials, the ability to raise additional necessary funds to continue to pursue ViewRay’s business and product development plans, the inherent uncertainties associated with the development of new products or technologies, competition in the industry in which ViewRay operates and general market conditions. For a more detailed description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay’s business generally, see ViewRay’s current and future reports filed with of the Securities and Exchange Commission, including its annual report on Form 10-K for the fiscal year ended December 31, 2021 and its quarterly reports on Form 10-Q, updated periodically along with the company’s other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay undertakes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. , except as required by law.

SOURCE ViewRay, Inc.

Comments are closed.